What does this research mean for the field?

KPC-producing Klebsiella pneumoniae infections exhibit extensive antibiotic resistance and confer a significantly higher risk of in-hospital mortality compared to non-KPC strains, with bloodstream infection and ICU admission acting as major independent risk factors. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 24, 2025Frontiers in Public Health1 citationsOpen Access

Clinical epidemiology and prognostic factors in patients with KPC-producing K. pneumoniae infections: a retrospective cohort study

QFQiangsheng Feng117th Hospital of People's Liberation Army YSYuejuan Song117th Hospital of People's Liberation Army XHXiaoqin Ha117th Hospital of People's Liberation Army

Key Points

Key points are not available for this paper at this time.

Abstract

Background This study aimed to investigate the clinical characteristics, drug resistance patterns, and prognosis of CRKP-infected patients. Methods This study evaluated in patients with carbapenemase-producing CRKP infection diagnosed through bacteriological evidence and clinical criteria over a 12-month period. Results KPC-producing Klebsiella pneumoniae represented 1.16% of all K. pneumoniae infections, the average patient age was 62.3 ± 20.2 years. Lung infection (58%) was the most common site, followed by bloodstream infection (22%) and urinary tract (11%) infections; 86% were nosocomial. Common comorbidities included cerebrovascular disease/cerebral infarction (23%), lung disease (16%), hematologic diseases/malignancies (12%), and viral pneumonia (12%). KPC-Kp exhibited high resistance (90%) to most tested antibiotics (including cephalosporins, piperacillin/tazobactam, fluoroquinolones, aztreonam, and carbapenems). Significantly lower resistance was observed only to tigecycline (5.1%) and ceftazidime-avibactam (CAZ-AVI) (4.3%). Non-KPC strains (NDM/VIM/OXA-48; n = 48) showed lower resistance (50%) to several agents and minimal resistance to tigecycline and CAZ-AVI (0–1.0%); resistance differences between KPC and non-KPC groups were highly significant ( p 0.001). KPC-Kp infection conferred significantly higher in-hospital mortality (46%) than non-KPC infections (10.4%; p 0.001), with nearly half (48%) of KPC-Kp deaths occurring within 7 days of infection. CAZ-AVI usage within the KPC-Kp group did not significantly improve 28-day survival (0.450 ± 0.132 vs. 0.573 ± 0.076, p = 0.317). Multivariate analysis identified significant independent risk factors for in-hospital mortality: KPC-Kp infection (OR 5.96, p 0.001), bloodstream infection (OR 8.57, p = 0.006), and ICU admission (OR 3.39, p = 0.006). Conclusion KPC-Kp infections demonstrated high incidence (1.16%), and severe mortality (46% in-hospital). Mortality risk was significantly elevated by KPC-Kp infection, bloodstream infection, and ICU admission, underscoring critical clinical threats.

Ask AI

Helpful

Bookmark

View Full Paper